Drug Profile
Research programme: polo-like protein kinase inhibitors - Amgen
Alternative Names: Plk-1 inhibitors -AmgenLatest Information Update: 09 Sep 2008
Price :
$50
*
At a glance
- Originator Amgen
- Class
- Mechanism of Action Polo-like kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 11 Apr 2006 Preclinical trials in Cancer in USA (unspecified route)